Morris Gabriel S, the CFO and President of Immix Biopharma, Inc., has reported an acquisition of 1,418 shares of the company. This transaction, dated November 18, 2026, is significant as it showcases the ongoing investment activities of key executives within the pharmaceutical sector.

Immix Biopharma, Inc. is classified under the SIC code for Pharmaceutical Preparations, indicating its involvement in the development and manufacturing of pharmaceutical products. The company is publicly traded under the symbol IMMX and is based in Los Angeles, California.

According to the recent SEC filing, Morris Gabriel S acquired the shares at a price of $7.06 each. Following this transaction, he holds a total of 292,847 shares directly. The filing specifies that Gabriel Morris is also the Managing Partner of Alwaysraise LLC and Alwaysraise Ventures I Investments, LLC, which hold additional shares, though he disclaims beneficial ownership of those securities beyond his pecuniary interest.

This update may affect investor sentiment and confidence in Immix Biopharma, as insider transactions are often scrutinized by market participants for indications of the company’s future performance. The pharmaceutical industry, characterized by its competitive nature and constant innovation, will likely continue to monitor such developments closely.

The filing does not say what happens next, leaving stakeholders to consider the implications of this acquisition on the company's strategic direction and market position.